Author:
Salem Mohamed,Garcia Jorge A.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, CA Cancer J Clin. 2010 Jul 7. [Epub ahead of print]
2. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol. 1998; 1160:1220–1229.
3. Ryan CJ. Secondary hormonal manipulations in prostate cancer. Hematol Oncol Clin North Am. 2006 Aug;20(4):925–34.
4. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med 351;15:1502–1512, 2004.
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, Volume: 351, Issue: 15 (2004), pp. 1513–1520
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献